WO2001028582A3 - Therapeutic applications of flint polypeptides - Google Patents

Therapeutic applications of flint polypeptides Download PDF

Info

Publication number
WO2001028582A3
WO2001028582A3 PCT/US2000/026241 US0026241W WO0128582A3 WO 2001028582 A3 WO2001028582 A3 WO 2001028582A3 US 0026241 W US0026241 W US 0026241W WO 0128582 A3 WO0128582 A3 WO 0128582A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic applications
flint
flint polypeptides
polypeptides
inhibiting
Prior art date
Application number
PCT/US2000/026241
Other languages
French (fr)
Other versions
WO2001028582A2 (en
Inventor
Thomas Frank Bumol
Fredric Jay Cohen
Original Assignee
Lilly Co Eli
Thomas Frank Bumol
Fredric Jay Cohen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Thomas Frank Bumol, Fredric Jay Cohen filed Critical Lilly Co Eli
Priority to EP00973379A priority Critical patent/EP1225908A2/en
Priority to AU11891/01A priority patent/AU1189101A/en
Publication of WO2001028582A2 publication Critical patent/WO2001028582A2/en
Publication of WO2001028582A3 publication Critical patent/WO2001028582A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FLINT protein is useful as a medicament in treating and/or inhibiting lung disorders and in inhibiting T cell proliferation. Therapeutic compositions and methods of treatment utilizing FLINT are provided.
PCT/US2000/026241 1999-10-20 2000-10-06 Therapeutic applications of flint polypeptides WO2001028582A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00973379A EP1225908A2 (en) 1999-10-20 2000-10-06 Therapeutic applications of flint polypeptides
AU11891/01A AU1189101A (en) 1999-10-20 2000-10-06 Therapeutic applications of flint polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16061399P 1999-10-20 1999-10-20
US60/160,613 1999-10-20

Publications (2)

Publication Number Publication Date
WO2001028582A2 WO2001028582A2 (en) 2001-04-26
WO2001028582A3 true WO2001028582A3 (en) 2001-11-08

Family

ID=22577617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026241 WO2001028582A2 (en) 1999-10-20 2000-10-06 Therapeutic applications of flint polypeptides

Country Status (3)

Country Link
EP (1) EP1225908A2 (en)
AU (1) AU1189101A (en)
WO (1) WO2001028582A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070174A (en) 1997-01-14 2000-11-25 벤슨 로버트 에이치. Tumor necrosis factor receptors 6α and 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
DE102007062411A1 (en) * 2007-12-20 2009-06-25 Justus-Liebig-Universität Giessen Medicines for the treatment of fibrosing lung diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050413A2 (en) * 1998-03-30 1999-10-07 Eli Lilly And Company THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
WO2000058466A2 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Protease resistant flint analogs
WO2000058465A2 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Flint polypeptide analogs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050413A2 (en) * 1998-03-30 1999-10-07 Eli Lilly And Company THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
WO2000058466A2 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Protease resistant flint analogs
WO2000058465A2 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Flint polypeptide analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARROP J A ET AL: "Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for (HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 42, 16 October 1998 (1998-10-16), pages 27548 - 27556, XP002109996, ISSN: 0021-9258 *
KUWANO KAZUYOSHI ET AL: "Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis.", JOURNAL OF CLINICAL INVESTIGATION, vol. 104, no. 1, July 1999 (1999-07-01), pages 13 - 19, XP002165816, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
WO2001028582A2 (en) 2001-04-26
AU1189101A (en) 2001-04-30
EP1225908A2 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
CA2315647A1 (en) Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
EP1449834A3 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
WO2001013906A3 (en) Compositions including modafinil for treatment of eating disorders and for appetite stimulation
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
NO984836L (en) Substituted benzylamines and their use in the treatment of depression
WO2001028582A3 (en) Therapeutic applications of flint polypeptides
HUP0003244A3 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
EP1009433A4 (en) Therapeutic composition and method of treatment
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
HUP0000812A3 (en) Peptide fragments of myelin basic protein, their pharmaceutical compositions and their use in treating multiple sclerosis
AU7132098A (en) Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases
AU779514C (en) Methods and compositions for use in gene therapy for treatment of hemophilia
GB9723824D0 (en) Cytostatic agents
AU2595201A (en) Antiviral therapeutic composition and treatment
AU2003216927A1 (en) Novel therapeutic composition for the prevention and treatment of hiv-1 infection in humans
AU5778098A (en) Therapeutic substance for use in the treatment of aids and immuno-allergical diseases
AU4125800A (en) Portable and folding table for massaging or any other type of treatment
AU2003200404A1 (en) Noribogaine in the treatment of pain and drug addiction
AU1756299A (en) Use of putamen ovi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000973379

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000973379

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000973379

Country of ref document: EP